FluoroPharma Medical, Inc. (OTCQB: FPMI), is a publicly traded company headquartered in Montclair NJ. It engages in the discovery, development and commercialization of proprietary medical diagnostic imaging products. The company’s initial focus is the development of breakthrough positron emission tomography (PET) imaging agents for the efficient detection and assessment of acute and chronic forms of coronary artery disease (CAD). Other products in development include agents for detection of inflamed atherosclerotic plaque in peripheral arteries, amyloid plaque in Alzheimer’s disease and agents for detection of certain types of cancer. SNNLive spoke with Thijs Spoor, Chairman, CEO and President of FluoroPharma Medical, Inc. at the LD Micro "Main Event" 2014 in Bel Air, CA.
Mr. Spoor begins with an overview of the company, “The company is investing in and developing molecular diagnostics. Basically what that means is we do high-res drugs for heart imaging. A lot of patients have a heart test, they go for a stress test and get images of the heart, we’re trying to make that high resolution, higher accuracy, lower radiation dose and better outcomes.”
He continues by explaining the importance of accuracy for these tests, “What we’re focusing on is really helping improve on both false-positives and false-negatives and what you find with the current standards of care is you actually get some patients who are told they have disease when they really don’t or they’ll tell they have some disease, but it’s actually a lot more than they actually think they have with the current standard of care test.”
He discusses what FluoroPharma has in store for 2015, “2015 is going to be a transformative year I think for the company, as we look at what we’re trying to do, we look to have data come out from this phase II trial that’s completing. We look to initiate another trial that we have for a blood flow agent, we also look to move all of our advanced discussions with our strategic partners forward.” For more information, check out their website: www.FluoroPharma.com
© 2017 Stock News Now
Supported by Superior Web Solutions